This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Montmorillonite is a purified clay indicated in the treatment of intestinal pain and diarrhea.
- Generic Name
- Montmorillonite
- DrugBank Accession Number
- DB13654
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Montmorillonite (DB13654)
- Weight
- Average: 360.307
Monoisotopic: 359.8254086 - Chemical Formula
- Al2H2O12Si4
- Synonyms
- Diosmectite
- Montmorillonite
- Montmorrillonite
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarbamazepine Montmorillonite can cause a decrease in the absorption of Carbamazepine resulting in a reduced serum concentration and potentially a decrease in efficacy. Chenodeoxycholic acid Montmorillonite can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Cholic Acid Montmorillonite can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Deferasirox Montmorillonite can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. Dehydrocholic acid Montmorillonite can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Deoxycholic acid Montmorillonite can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Dolutegravir The serum concentration of Dolutegravir can be decreased when it is combined with Montmorillonite. Eltrombopag Montmorillonite can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. Halofantrine Montmorillonite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. Mephenytoin Montmorillonite can cause a decrease in the absorption of Mephenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DIMECTAL Powder for Oral Suspension 3g Powder 3 g Oral PAHANG PHARMACY SDN. BHD. 2021-12-02 Not applicable Malaysia 
FOTAGEL SUSPENSION 3g/20ml (DIOCTAHEDRAL SMECTITE) Suspension 3 g/20ml Oral IMEKS PHARMA SDN. BHD. 2020-09-08 Not applicable Malaysia hovid Diosmectite Oral Suspension 1g/10mL Suspension Oral Hovid Berhad 2020-09-08 Not applicable Malaysia IPRIKENE Powder 3.000 g Oral 2012-01-03 Not applicable Mexico Smecta Orange-Vanilla Flavour Powder for Oral Suspension 3g Powder, for suspension Oral EP PLUS GROUP SDN. BHD. 2020-09-08 Not applicable Malaysia SMECTA SACHET 3 g/sachet Powder 3 g/sachet Oral EMERGING PHARMA (S) PTE LTD 1991-03-07 Not applicable Singapore Smecta Strawberry Flavour Powder for Oral Suspension 3g Powder, for suspension Oral EP PLUS GROUP SDN. BHD. 2020-09-08 Not applicable Malaysia SmectaGo 3g Oral Suspension In Sachet Suspension 3 g Oral EP PLUS GROUP SDN. BHD. 2020-09-08 Not applicable Malaysia - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dr. SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampoo Montmorillonite (0.088 g/100mL) + Lime (citrus) (0.0174 g/100mL) + Melaleuca alternifolia leaf (1 g/100mL) Shampoo Topical Saturday9 Co., Ltd. 2023-02-21 Not applicable US 
Categories
- ATC Codes
- A07BC05 — Diosmectite
- Drug Categories
- Alimentary Tract and Metabolism
- Aluminium Compounds
- Aluminum Silicates
- Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
- Antidotes
- Compounds used in a research, industrial, or household setting
- Intestinal Adsorbents
- Metal cations
- Metal divalent cations
- Minerals
- Oxides
- Oxygen Compounds
- Protective Agents
- Silicates
- Silicon Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as post-transition metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a post-transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Post-transition metal organides
- Sub Class
- Post-transition metal oxides
- Direct Parent
- Post-transition metal oxides
- Alternative Parents
- Post-transition metal salts / Metalloid salts / Inorganic salts / Inorganic oxides
- Substituents
- Inorganic metalloid salt / Inorganic oxide / Inorganic post-transition metal salt / Inorganic salt / Post-transition metal oxide
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A585MN1H2L
- CAS number
- 1318-93-0
- InChI Key
- GUJOJGAPFQRJSV-UHFFFAOYSA-N
- InChI
- InChI=1S/2Al.4O2Si.H2O.3O/c;;4*1-3-2;;;;/h;;;;;;1H2;;;/q2*+3;;;;;;3*-2
- IUPAC Name
- dialuminium(3+) ion tetrakis(silanedione) hydrate trioxidandiide
- SMILES
- O.[O--].[O--].[O--].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O
References
- General References
- External Links
- ChemSpider
- 32699070
- 1425919
- Wikipedia
- Montmorillonite
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Acute Diarrhea 1 4 Completed Treatment Berberine / Coronavirus Disease 2019 (COVID‑19) 1 4 Completed Treatment Diarrhea 1 4 Completed Treatment Gastroesophageal Reflux in Neonates 1 3 Completed Treatment Diarrhea / Diarrhoea 2 3 Terminated Treatment High Output Stoma 1 2 Withdrawn Treatment Cancer 1 2, 3 Recruiting Prevention Breast Cancer 1 1 Completed Other Chronic Functional Diarrhea of Unknown Origin 1 1 Completed Treatment HER2-positive Recurrent / Metastatic Breast Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Oral 3 g Powder, for solution Oral 78.97 g Powder, for solution Oral Powder, for suspension Oral 3 G Shampoo Topical Powder, for solution Oral 3000 mg Suspension Oral 3 g/20ml Suspension Oral Powder Oral 3.000 g Suspension Oral 10 g Powder, for suspension Oral Powder Oral Powder Oral 3 g/sachet Suspension Oral 3 g Powder, for solution Oral 3 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.66 Chemaxon pKa (Strongest Basic) -8.5 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 34.14 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 2.89 m3·mol-1 Chemaxon Polarizability 3.28 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12